Amgen (AMGN) Tops Q3 EPS by 24c, FY Guidance Tops Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. SPY
3. PTC
4. META
5. PCVX
6. USO
7. MSFT
8. AMZN
9. AMD
10. ATH

Go back to Amgen (AMGN) Tops Q3 EPS by 24c, FY Guidance Tops Views

Amgen Reports Third Quarter 2018 Financial Results

October 30, 2018 4:01 PM EDT

THOUSAND OAKS, Calif., Oct. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2018. Key results include:

Total revenues increased 2 percent versus the third quarter of 2017 to $5.9 billion. Product sales grew 1 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth.GAAP earnings per share (EPS) increased 4 percent to $2.86 driven by higher total revenues, a lower tax rate and lower weighted-average shares outstanding. GAAP operating income decreased... More